Taysha Gene Therapies (TSHA) is scheduled to report earnings on May 13, 2025. The last reported earnings were for reported on February 26, 2025 for Q4. The Actual Revenue was $2M, which beat the ...

High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6 ...

Taysha Gene Therapies Stock Down 1.7 % Shares of NASDAQ:TSHA opened at $1.72 on Tuesday. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The ...

Shares of TSHA opened at $1.60 on Thursday. The company has a market cap of $327.91 million, a price-to-earnings ratio of 2.54 and a beta of 0.93. Taysha Gene Therapies has a 1-year low of $1.19 ...

1 Day TSHA 0.62% DJIA -0.37% Russell 2K -0.10% Health Care/Life Sciences 0.69% ...